Friday, December 9, 2022, 7:00 PM – 9:00 PM CT (8:00 PM – 10:00 PM ET) – New Orleans, Louisiana

Addressing Current Questions and Controversies in the Management of Multiple Myeloma — What Clinicians Want to Know (Part 3 of a 3-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 64th ASH Annual Meeting

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Hotel Phone: (504) 561-1234

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Celestin Ballroom ABCD (Level 3)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
 
Faculty
Jesús G Berdeja, MD
Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Rafael Fonseca, MD
Chief Innovation Officer
Getz Family Professor of Cancer
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia


Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Front-Line Treatment of Multiple Myeloma (MM) — Dr Orlowski

  • Long-term findings with daratumumab-containing regimens for newly diagnosed MM; role for transplant-eligible and ineligible patients
  • Published data and ongoing evaluation with novel daratumumab-based quadruplet regimens for newly diagnosed transplant-eligible patients
  • Similarities and differences between daratumumab and isatuximab
  • Key findings from the Phase III GMMG HD7 trial comparing isatuximab with RVd to RVd alone for transplant-eligible patients with newly diagnosed MM
  • Ongoing Phase III studies of isatuximab as a part of induction therapy for transplant-eligible and ineligible patients
  • Available data with and current role of minimal residual disease assessment in therapeutic decision-making

MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Fonseca

  • Results from the Phase III ICARIA-MM study leading to the FDA approval of isatuximab with pomalidomide and dexamethasone for multiregimen-relapsed MM
  • Updates from the Phase III IKEMA trial of isatuximab/carfilzomib/dexamethasone; progression-free survival improvement in comparison to other proteasome inhibitor-containing combinations in the second-line setting
  • Key findings from the Phase III BOSTON trial and FDA approval of selinexor with bortezomib/dexamethasone for R/R MM
  • Early results with other selinexor-containing combinations in R/R MM
  • Key findings supporting the FDA approval of belantamab mafodotin monotherapy for R/R MM; implications, if any, of emerging results from the Phase III DREAMM-3 study
  • Early data with belantamab mafodotin combined with other systemic therapies and/or in earlier lines of treatment

MODULE 3: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje

  • Structural makeup and manufacturing of available BCMA-directed CAR T-cell platforms
  • Results from the Phase II KarMMa trial evaluating idecabtagene vicleucel (ide-cel) for R/R MM
  • Key data from the CARTITUDE-1 trial of ciltacabtagene autoleucel (cilta-cel) for pretreated MM
  • FDA approvals of ide-cel and cilta-cel for heavily pretreated MM
  • Available and emerging data with and ongoing studies of BCMA-targeted CAR T-cell therapies in earlier lines of treatment
  • Incidence, severity and management of toxicities with BCMA-targeted CAR T-cell therapies
  • Early data and ongoing research with non-BCMA CAR T-cell platforms

MODULE 4: Bispecific Antibodies in the Treatment of MM — Dr Berdeja

  • Similarities and differences in the cellular targets and mechanisms of action of bispecific antibodies in MM
  • Activity of teclistamab in the Phase I/II MajesTEC-1 study and accelerated FDA approval for R/R MM
  • Responses observed with elranatamab in the pivotal Phase II MagnetisMM-3 trial for R/R MM
  • Early-phase findings with other anti-BCMA bispecific antibody constructs for heavily pretreated MM
  • Biologic rationale for and available data with non-BCMA-targeted bispecific antibodies (eg, talquetamab, cevostamab); FDA breakthrough therapy designation for talquetamab
  • Spectrum, incidence, severity and management of toxicities with bispecific antibodies
  • Ongoing research with bispecific antibodies as monotherapy or with other systemic therapies

MODULE 5: Other Investigational Novel Agents for MM — Dr Lonial

  • Published data with and current role of venetoclax-based therapy for patients with MM and t(11;14) or Bcl-2 overexpression
  • Design, eligibility criteria and key endpoints of the Phase III CANOVA trial evaluating venetoclax/dexamethasone versus pomalidomide/dexamethasone for R/R t(11;14) MM; other ongoing studies of venetoclax-based combinations
  • Mechanism of action of cereblon E3 ligase modulators (CELMoDs); similarities and differences between CELMoDs and standard immunomodulatory drugs
  • Activity and safety observed with CELMoDs in patients with heavily pretreated MM
  • Other promising novel strategies in development

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Customize the selection of first-line therapy for patients with newly diagnosed MM, considering new clinical research and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplant.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplantation, and assess when and how this strategy should be integrated into disease management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory MM.
  • Understand the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies to facilitate their integration into MM management algorithms.
  • Evaluate the biologic rationale for the use of chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom this novel approach should be considered.
  • Assess available research findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and use this knowledge to identify patients who may be appropriate candidates for these approaches within or outside of a protocol setting.
  • Recall the design of ongoing studies evaluating other novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Berdeja — Consulting Agreements: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, CRISPR Therapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Secura Bio, Takeda Pharmaceuticals USA Inc; Contracted Research: 2seventy bio, AbbVie Inc, Acetylon Pharmaceuticals, Amgen Inc, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, CARsgen Therapeutics, Cartesian Therapeutics, Celgene Corporation, Celularity, CRISPR Therapeutics, EMD Serono Inc, Fate Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Ichnos Sciences, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Lilly, Novartis, Poseida Therapeutics, Sanofi, Takeda Pharmaceuticals USA Inc, Teva Oncology, Zentalis Pharmaceuticals. Dr Fonseca — Consulting Agreements: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, H3 Biomedicine, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Merck, Novartis, Oncopeptides, ONCOtracker, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Scientific Advisory Board: Adaptive Biotechnologies Corporation, Caris Life Sciences, OncoMyx Therapeutics, ONCOtracker. Dr Lonial — Advisory Committee: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Board of Directors with Stock: TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc. Dr Orlowski — Advisory Committee and Consulting Agreements: AbbVie Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Clinical Research Funding: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, BioTheryX Inc, Heidelberg Pharma. Dr Raje — Advisory Committee: bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Immuneel Therapeutics, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Pharmaceuticals USA Inc; Contracted Research: bluebird bio; Steering Committee: Amgen Inc, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi.

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 561-1234

Meeting Room
Celestin Ballroom ABCD (Level 3)

Directions
Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our onsite registration desk will be open at 6:30 PM CT on Friday, December 9th. If you are interested in attending, please visit our registration desk outside the Celestin Ballroom ABCD (Level 3) of the Hyatt Regency New Orleans hotel (601 Loyola Avenue).

Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting.

LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.